340B TB modifier reporting and payment for Part B drugs
Customize your policy alerts
Sign up for all Aspirus Arise policy alerts
Know when Aspirus Arise releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Aspirus Medicare Advantage billing and payment expectations for drugs and biologicals acquired through the 340B Drug Pricing Program, including required use of modifier TB and related payment methodology for hospital outpatient services.
As of January 1, 2025, CMS requires all 340B covered entities to exclusively report modifier 'TB' on claim lines for drugs acquired through the 340B Drug Discount Program.
Effective for claims paid on or after September 28, 2022, Aspirus implemented payment updates to allow the full rate (generally ASP plus 6%) for 340B purchased drugs in accordance with CMS guidance.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.